MARTHAS VINEYARD HOSPITAL
1. Target Overview & Investment Thesis
MARTHAS VINEYARD HOSPITAL is a 25-bed rural/critical access in DUKES, MA with $121.6M in net patient revenue and a 3.2% operating margin. The hospital serves a payer mix of 63.6% Medicare, 15.9% Medicaid, and 20.5% commercial.
Thesis: Turnaround. Our ML models identify $9.0M in annual EBITDA improvement potential from RCM optimization across 5 levers, lifting margin from 3.2% to 10.6% (+736bps).
| Net Revenue HCRIS | $121.6M |
| Current EBITDA COMPUTED | $3.9M |
| Operating Margin COMPUTED | 3.2% |
| Occupancy HCRIS | 46.4% |
| Revenue / Bed COMPUTED | $4.9M |
| Net-to-Gross HCRIS | 53.3% |
| Distress Probability ML | 50.4% |
2. Market Context & Competitive Position
MA has 99 Medicare-certified hospitals with a median operating margin of -12.2%. The target's margin of 3.2% places it above the state median. Among 11 size-comparable peers (12-50 beds), the median margin is -26.0%. The target performs in line with or above peers.
3. RCM Performance Analysis — Comparable Hospitals
Comps selected by bed count (12-50), prioritizing same-state peers. 11 hospitals in the comp set.
| Hospital | State | Beds | Revenue | Margin |
|---|---|---|---|---|
| MARTHAS VINEYARD HOSPITAL (Target) | MA | 25 | $121.6M | 3.2% |
| DANA-FARBER CANCER INSTITUTE | MA | 30 | $1.88B | -35.1% |
| MASSACHUSETTS EYE AND EAR INFI | MA | 41 | $263.9M | -36.1% |
| FAIRVIEW HOSPITAL | MA | 24 | $94.5M | 19.8% |
| BAYSTATE WING HOSPITAL & MEDIC | MA | 40 | $91.8M | -16.8% |
| NANTUCKET COTTAGE HOSPITAL | MA | 14 | $65.3M | -25.8% |
| ATHOL MEMORIAL HOSPITAL | MA | 21 | $30.3M | -26.1% |
| WHITTIER HOSPITAL-BRADFORD | MA | 35 | $27.6M | -5.1% |
| CHESTNUT HILL BENEVOLENT ASSOC | MA | 20 | $2.8M | -50.0% |
4. Predicted Improvement Opportunities
Improvement targets set at P75 of comparable peers with 60% gap closure assumption. Coefficients calibrated to published research bands. Total EBITDA uplift: $9.0M (736bps margin improvement).
| Lever | Current | Target | EBITDA Impact | Margin | Ramp |
|---|---|---|---|---|---|
| Net Collection Rate | 93.5% | 97.0% | $2.6M | +210bp | 18mo |
| Cost to Collect | 4.5% | 2.5% | $2.4M | +200bp | 12mo |
| Denial Rate Reduction | 12.0% | 6.5% | $2.4M | +198bp | 12mo |
| A/R Days Reduction | 5200.0% | 3800.0% | $1.5M | +122bp | 9mo |
| Clean Claim Rate | 88.0% | 96.0% | $78K | +6bp | 6mo |
5. EBITDA Bridge
| Current EBITDA | $3.9M |
| + RCM Uplift | +$9.0M |
| Pro Forma EBITDA | $12.9M |
| Current Margin | 3.2% |
| Pro Forma Margin | 10.6% |
| WC Released (1x) | $4.7M |
6. Returns Analysis — Scenario Matrix
5-year hold, 5.5x leverage, 3% organic growth, 10%/yr debt paydown. Base case uses 100% of predicted RCM uplift. Bull case: 130% uplift at lower entry. Bear case: 50% uplift at higher entry.
| Scenario | Entry | Exit | Equity In | Equity Out | MOIC | IRR |
|---|---|---|---|---|---|---|
| Base Case | 10.0x | 10.0x | $6.0M | $115.2M | 19.20x | 80.6% |
| Base (11x exit) | 10.0x | 11.0x | $6.0M | $128.7M | 21.45x | 84.6% |
| Bull Case | 9.0x | 11.0x | $5.4M | $160.2M | 29.66x | 97.0% |
| Bull (12x exit) | 9.0x | 12.0x | $5.4M | $176.4M | 32.65x | 100.8% |
| Bear Case | 11.0x | 10.0x | $6.6M | $68.5M | 10.38x | 59.7% |
| Bear (11x exit) | 11.0x | 11.0x | $6.6M | $77.5M | 11.75x | 63.7% |
7. Key Risks & Mitigants
| Severity | Risk Factor | Mitigant |
|---|---|---|
| Medium | Heavy Medicare dependence | Medicare comprises 63.6% of days; rate updates may lag inflation. Mitigant: CDI/CMI lever directly increases Medicare reimbursement |
| High | Elevated distress probability | Model estimates 50.4% probability of financial distress. Mitigant: distressed entry pricing (7-9x) compensates for risk |
8. Data Sources & Methodology Appendix
Data Sources
- CMS HCRIS Cost Reports (Medicare-certified hospitals)
- CMS Medicare Utilization (DRG-level volumes)
- CMS Chronic Conditions (county-level disease prevalence)
- HCRIS multi-year trend data (financial time series)
Comparable Selection
- 11 hospitals with 12-50 beds
- Same-state prioritization (n=12)
- Comp margins: P25=-35.3% / P50=-26.0% / P75=-13.9%
Bridge Methodology
- Targets: P75 of comparable peers (60% gap closure)
- Denial: avoidable share = 35% of delta × NPR
- AR: bad debt coefficient = $0.65 per day per $1K NPR
- NCR: 60% coefficient on collection rate improvement
- CDI: 0.75% of Medicare revenue per 0.01 CMI point
Returns Assumptions
- Leverage: 5.5x entry (84.6% debt / 15.4% equity)
- Organic growth: 3% annual EBITDA growth
- Debt paydown: 10% of principal per year
- Hold period: 5 years
Generated by SeekingChartis on April 26, 2026. All predictions use public data only. Confidence intervals calibrated via split conformal prediction (90% coverage target). This memo is for informational purposes and does not constitute investment advice.